These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Agomelatine-Induced Maculopapular Rash: A Case Report. Okan Ibiloğlu A; Tamam L Noro Psikiyatr Ars; 2013 Dec; 50(4):379-380. PubMed ID: 28360575 [No Abstract] [Full Text] [Related]
30. Agomelatine and migraine management: a successfully treated case series. Plasencia-García BO; Romero-Guillena SL; Quirós-López A; Ruiz-Doblado S Ther Adv Psychopharmacol; 2015 Aug; 5(4):243-5. PubMed ID: 26301081 [No Abstract] [Full Text] [Related]
31. Agomelatine - is it another reboxetine? Another case of publication bias. Gupta S Psychiatr Bull (2014); 2014 Apr; 38(2):88. PubMed ID: 25237511 [No Abstract] [Full Text] [Related]
32. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049 [TBL] [Abstract][Full Text] [Related]
33. Effects of long-term agomelatine treatment on the cognitive performance and hippocampal plasticity of adult rats. Demir Özkay Ü; Söztutar E; Can ÖD; Üçel Uİ; Öztürk Y; Ulupinar E Behav Pharmacol; 2015 Aug; 26(5):469-80. PubMed ID: 26110225 [TBL] [Abstract][Full Text] [Related]
34. Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia. Gupta S; Singh P; Sharma BM; Sharma B Curr Neurovasc Res; 2015; 12(3):240-52. PubMed ID: 26036976 [TBL] [Abstract][Full Text] [Related]
35. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Carvalho AF; Sharma MS; Brunoni AR; Vieta E; Fava GA Psychother Psychosom; 2016; 85(5):270-88. PubMed ID: 27508501 [TBL] [Abstract][Full Text] [Related]
37. Psychiatric disorders and sexual dysfunction. Waldinger MD Handb Clin Neurol; 2015; 130():469-89. PubMed ID: 26003261 [TBL] [Abstract][Full Text] [Related]
38. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA). Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863 [TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for the treatment of anxiety. Murrough JW; Yaqubi S; Sayed S; Charney DS Expert Opin Emerg Drugs; 2015 Sep; 20(3):393-406. PubMed ID: 26012843 [TBL] [Abstract][Full Text] [Related]
40. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine. Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]